Published 1 year ago • loading... • Updated 1 year ago

AstraZeneca to build $2.5B research hub in Beijing

AstraZeneca plans to build a $2.5 billion research and development center in Beijing, as announced by the company on Friday.
This center will increase AstraZeneca's workforce in Beijing to approximately 1,700, according to the company's statement.
AstraZeneca is partnering with the Beijing government and three Chinese biotech firms as part of this project.
CEO Pascal Soriot stated that this investment reflects AstraZeneca's commitment to China's life sciences ecosystem.

Insights by Ground AI

19 Articles

AstraZeneca to invest US$ 2.5 billion in a new research center in China, where it is being investigated

The unit will be the company's second in China, after its research center in Shanghai, and will be added to two more in Europe and two in the USA

1 year ago·Brazil

Read Full Article

The Telegraph

Lean Right

AstraZeneca to invest £2bn in Beijing amid China investigation

Pharmaceutical giant scrambles to contain scandal over alleged illegal drug imports

1 year ago·London, United Kingdom

Read Full Article

Pharmaphorum

Center

AZ builds in China, as J&J ramps up its US investments

AstraZeneca will open its sixth R&D centre in China, while J&J announces four new manufacturing facilities in the US in a major reshoring drive.

1 year ago

Read Full Article

UPI

Center

AstraZeneca to build $2.5B research hub in Beijing

AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational pharmaceutical announced Friday.

1 year ago·Washington, United States

Read Full Article

biopharmadive.com

Center

AstraZeneca deepens China investment; Editas loses CFO to Dyne

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

1 year ago

Read Full Article